Cargando…
Giant Cell Tumor of Bone in Patients under 16 Years Old: A Single-Institution Case Series
SIMPLE SUMMARY: Giant cell tumor of the bone is a locally aggressive, rarely metastasizing tumor that accounts for about 5% of bone tumors; it generally occurs in patients between 20 and 45 years old. Sporadic cases (less than 140) have been described as occurring in the first two decades of life. A...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197501/ https://www.ncbi.nlm.nih.gov/pubmed/34070432 http://dx.doi.org/10.3390/cancers13112585 |
_version_ | 1783706931887603712 |
---|---|
author | Ambrosi, Francesca Righi, Alberto Benini, Stefania Magagnoli, Giovanna Chiaramonte, Ilaria Manfrini, Marco Gasbarrini, Alessandro Frisoni, Tommaso Gambarotti, Marco |
author_facet | Ambrosi, Francesca Righi, Alberto Benini, Stefania Magagnoli, Giovanna Chiaramonte, Ilaria Manfrini, Marco Gasbarrini, Alessandro Frisoni, Tommaso Gambarotti, Marco |
author_sort | Ambrosi, Francesca |
collection | PubMed |
description | SIMPLE SUMMARY: Giant cell tumor of the bone is a locally aggressive, rarely metastasizing tumor that accounts for about 5% of bone tumors; it generally occurs in patients between 20 and 45 years old. Sporadic cases (less than 140) have been described as occurring in the first two decades of life. A histone 3.3 (H3.3) gene, H3F3A, has been recently identified in as many as 96% of giant cell tumors of bone. These mutations are useful in the differential diagnosis of giant cell tumor of bone with its mimickers. The immunohistochemical expression of H3F3A resulted comparable to molecular analysis as reported in a recent investigation. In the present study, we describe our series of giant cell tumors of bone in pediatric patients <16 years old. ABSTRACT: Background: Giant cell tumor of bone is a locally aggressive, rarely metastasizing tumor that accounts for about 5% of bone tumors and generally occurs in patients between 20 and 45 years old. A driver mutation in the histone 3.3 (H3.3) gene H3F3A has been identified in as many as 96% of giant cell tumors of bone. The immunohistochemical expression of H3F3A H3.3 G34 expression was found in 97.8% of cases. In the present study, we describe our series of cases of giant cell tumor of bone in pediatric patients <16 years old. Methods: All cases of giant cell tumor of bone in pediatric patients <16 years old treated in our institute between 1982 and 2018 were reviewed. Immunohistochemistry and/or molecular analysis for H3F3A gene mutations was performed to confirm the diagnosis. A group of aneurysmal bone cysts in patients <16 years old was used as a control group. Results: Fifteen cases were retrieved. A pronounced female predominance (93%) was observed. A pure metaphyseal central location occurs in 2 skeletally immature patients. Conclusions: Giant cell tumor of bone should be distinguished from its mimickers due to differences in prognosis and treatment. Immunohistochemical and molecular detection of H3F3A gene mutation represents a reliable diagnostic tool. |
format | Online Article Text |
id | pubmed-8197501 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81975012021-06-13 Giant Cell Tumor of Bone in Patients under 16 Years Old: A Single-Institution Case Series Ambrosi, Francesca Righi, Alberto Benini, Stefania Magagnoli, Giovanna Chiaramonte, Ilaria Manfrini, Marco Gasbarrini, Alessandro Frisoni, Tommaso Gambarotti, Marco Cancers (Basel) Article SIMPLE SUMMARY: Giant cell tumor of the bone is a locally aggressive, rarely metastasizing tumor that accounts for about 5% of bone tumors; it generally occurs in patients between 20 and 45 years old. Sporadic cases (less than 140) have been described as occurring in the first two decades of life. A histone 3.3 (H3.3) gene, H3F3A, has been recently identified in as many as 96% of giant cell tumors of bone. These mutations are useful in the differential diagnosis of giant cell tumor of bone with its mimickers. The immunohistochemical expression of H3F3A resulted comparable to molecular analysis as reported in a recent investigation. In the present study, we describe our series of giant cell tumors of bone in pediatric patients <16 years old. ABSTRACT: Background: Giant cell tumor of bone is a locally aggressive, rarely metastasizing tumor that accounts for about 5% of bone tumors and generally occurs in patients between 20 and 45 years old. A driver mutation in the histone 3.3 (H3.3) gene H3F3A has been identified in as many as 96% of giant cell tumors of bone. The immunohistochemical expression of H3F3A H3.3 G34 expression was found in 97.8% of cases. In the present study, we describe our series of cases of giant cell tumor of bone in pediatric patients <16 years old. Methods: All cases of giant cell tumor of bone in pediatric patients <16 years old treated in our institute between 1982 and 2018 were reviewed. Immunohistochemistry and/or molecular analysis for H3F3A gene mutations was performed to confirm the diagnosis. A group of aneurysmal bone cysts in patients <16 years old was used as a control group. Results: Fifteen cases were retrieved. A pronounced female predominance (93%) was observed. A pure metaphyseal central location occurs in 2 skeletally immature patients. Conclusions: Giant cell tumor of bone should be distinguished from its mimickers due to differences in prognosis and treatment. Immunohistochemical and molecular detection of H3F3A gene mutation represents a reliable diagnostic tool. MDPI 2021-05-25 /pmc/articles/PMC8197501/ /pubmed/34070432 http://dx.doi.org/10.3390/cancers13112585 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ambrosi, Francesca Righi, Alberto Benini, Stefania Magagnoli, Giovanna Chiaramonte, Ilaria Manfrini, Marco Gasbarrini, Alessandro Frisoni, Tommaso Gambarotti, Marco Giant Cell Tumor of Bone in Patients under 16 Years Old: A Single-Institution Case Series |
title | Giant Cell Tumor of Bone in Patients under 16 Years Old: A Single-Institution Case Series |
title_full | Giant Cell Tumor of Bone in Patients under 16 Years Old: A Single-Institution Case Series |
title_fullStr | Giant Cell Tumor of Bone in Patients under 16 Years Old: A Single-Institution Case Series |
title_full_unstemmed | Giant Cell Tumor of Bone in Patients under 16 Years Old: A Single-Institution Case Series |
title_short | Giant Cell Tumor of Bone in Patients under 16 Years Old: A Single-Institution Case Series |
title_sort | giant cell tumor of bone in patients under 16 years old: a single-institution case series |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197501/ https://www.ncbi.nlm.nih.gov/pubmed/34070432 http://dx.doi.org/10.3390/cancers13112585 |
work_keys_str_mv | AT ambrosifrancesca giantcelltumorofboneinpatientsunder16yearsoldasingleinstitutioncaseseries AT righialberto giantcelltumorofboneinpatientsunder16yearsoldasingleinstitutioncaseseries AT beninistefania giantcelltumorofboneinpatientsunder16yearsoldasingleinstitutioncaseseries AT magagnoligiovanna giantcelltumorofboneinpatientsunder16yearsoldasingleinstitutioncaseseries AT chiaramonteilaria giantcelltumorofboneinpatientsunder16yearsoldasingleinstitutioncaseseries AT manfrinimarco giantcelltumorofboneinpatientsunder16yearsoldasingleinstitutioncaseseries AT gasbarrinialessandro giantcelltumorofboneinpatientsunder16yearsoldasingleinstitutioncaseseries AT frisonitommaso giantcelltumorofboneinpatientsunder16yearsoldasingleinstitutioncaseseries AT gambarottimarco giantcelltumorofboneinpatientsunder16yearsoldasingleinstitutioncaseseries |